FDA Approves First RNA-Targeted Treatment for Hereditary Angioedema
The approval makes donidalorsen the only treatment in the US for hereditary angioedema that is an RNA-targeted prophylactic.
Previous Post
Viking’s obesity flop, ‘pharma to table’ drug sales
Next Post
First-Line Sacituzumab Tirumotecan Combo Improves Advanced NSCLC Outcomes
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago